Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Naveen Karkada"'
Autor:
Shangying Hu, Xiaoqian Xu, Fengcai Zhu, Ying Hong, Yuemei Hu, Xun Zhang, Qinjing Pan, Wenhua Zhang, Chengfu Zhang, Xiaoping Yang, Jiaxi Yu, Jiahong Zhu, Yejiang Zhu, Feng Chen, Shuang Zhao, Naveen Karkada, Haiwen Tang, Dan Bi, Frank Struyf, Fanghui Zhao
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 4, Pp 955-964 (2021)
Human papillomavirus (HPV) vaccines are efficacious against HPV infections and associated lesions in women HPV-naïve at vaccination. However, vaccine efficacy (VE) against oncogenic, high-risk HPV (HR-HPV) types in women infected with any other HR-H
Externí odkaz:
https://doaj.org/article/a714e90d323d46e2bac37315b739bea5
Autor:
Ashish Agrawal, Shafi Kolhapure, Anar Andani, Martin O. C. Ota, Selim Badur, Naveen Karkada, Monjori Mitra
Publikováno v:
Infectious Diseases and Therapy, Vol 9, Iss 4, Pp 785-796 (2020)
Abstract Introduction Hepatitis A virus infection is more severe in adults than children. Although vaccination can protect adults, current childhood programs cover a large population more successfully. Childhood vaccination is, therefore, a solution
Externí odkaz:
https://doaj.org/article/b4111448187241bdb9099bd61a6e323e
Autor:
Feng‐Cai Zhu, Shang‐Ying Hu, Ying Hong, Yue‐Mei Hu, Xun Zhang, Yi‐Ju Zhang, Qin‐Jing Pan, Wen‐Hua Zhang, Fang‐Hui Zhao, Cheng‐Fu Zhang, Xiaoping Yang, Jia‐Xi Yu, Jiahong Zhu, Yejiang Zhu, Feng Chen, Qian Zhang, Hong Wang, Changrong Wang, Jun Bi, Shiyin Xue, Lingling Shen, Yan‐Shu Zhang, Yunkun He, Haiwen Tang, Naveen Karkada, Pemmaraju Suryakiran, Dan Bi, Frank Struyf
Publikováno v:
Cancer Medicine, Vol 8, Iss 14, Pp 6195-6211 (2019)
Abstract Background Cervical cancer is a major public health concern in China. We report the end‐of‐study results of a phase II/III trial to assess the efficacy, immunogenicity, and safety of the AS04‐human papillomavirus (HPV)‐16/18 vaccine
Externí odkaz:
https://doaj.org/article/7eafe7b507044933b700ba50d3514abc
Autor:
Tino F. Schwarz, Li-Min Huang, Alejandra Valencia, Falko Panzer, Cheng-Hsun Chiu, Annabelle Decreux, Sylviane Poncelet, Naveen Karkada, Nicolas Folschweiller, Lan Lin, Gary Dubin, Frank Struyf
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 7-8, Pp 1970-1979 (2019)
This study assessed long-term immunogenicity and safety following 3 doses of AS04-adjuvanted human papillomavirus (HPV)-16/18 L1 virus-like particle (VLP) vaccine in females 10–14 years old. Girls included in the immunogenicity subset in the primar
Externí odkaz:
https://doaj.org/article/12db5ea015de4256acac886bf78b7c59
Autor:
Martin Ryser, Valérie Berlaimont, Naveen Karkada, Attila Mihalyi, Rino Rappuoli, Robbert van der Most
Publikováno v:
Expert Review of Vaccines, Vol 18, Iss 3, Pp 309-322 (2019)
Background: Substantial heterogeneity has been reported in efficacy against high-grade cervical intraepithelial neoplasia (CIN) irrespective of HPV type in phase III results for bivalent and quadrivalent human papillomavirus virus (HPV) vaccines (AS0
Externí odkaz:
https://doaj.org/article/45f9a6cd592643069c26e8d7469e7e67
Autor:
Ki Hwan Kim, Chun Soo Kim, Hwang Min Kim, Jong-Duck Kim, Sang Hyuk Ma, Dong Ho Kim, Pyoung-Han Hwang, Ji-Whan Han, Taek-Jin Lee, Joon Hyung Kim, Naveen Karkada, Narcisa Mesaros, Woo-Yun Sohn, Jong-Hyun Kim
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 2, Pp 317-326 (2019)
We assessed the immunogenicity and safety of a three-dose primary vaccination schedule with the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus/Haemophilus influenzae type b vaccine (DTPa-IPV/Hib) in Korean infants. In this pha
Externí odkaz:
https://doaj.org/article/c575118217734c12a8a4696e16dd74e4
Autor:
Yanping Li, Rong Cheng Li, Qiang Ye, Changgui Li, You Ping Liu, Xiao Ma, Yanan Li, Hong Zhao, Xiaoling Chen, Deepak Assudani, Naveen Karkada, Htay Htay Han, Olivier Van Der Meeren, Narcisa Mesaros
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 3, Pp 588-598 (2017)
We conducted 3 phase III, randomized, open-label, clinical trials assessing the safety, reactogenicity (all studies), immunogenicity (Primary vaccination study) and persistence of immune responses (Booster study) to the combined diphtheria, tetanus,
Externí odkaz:
https://doaj.org/article/fb921f0885c8412fb3ac19e42dce9a4e
Autor:
Sanjay K. Lalwani, Sharad Agarkhedkar, Balasubramanian Sundaram, Niranjana S. Mahantashetti, Nandini Malshe, Shalaka Agarkhedkar, Olivier Van Der Meeren, Shailesh Mehta, Naveen Karkada, Htay Htay Han, Narcisa Mesaros
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 1, Pp 120-127 (2017)
Multivalent combination vaccines have reduced the number of injections and therefore improved vaccine acceptance, timeliness of administration and global coverage. The hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovir
Externí odkaz:
https://doaj.org/article/74df3590d8e14f68b1dcac7fc7378524
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 1, Pp 237-244 (2017)
In 2010, porcine circovirus type 1 (PCV1) material was unexpectedly detected in the oral live-attenuated human rotavirus (RV) vaccine, Rotarix™ (GSK Vaccines, Belgium). An initial study (NCT01511133) found no immunologic response against PCV1 in 40
Externí odkaz:
https://doaj.org/article/f04090e835134f7aa042602bbce8a969
Publikováno v:
Pharmaceutical statisticsREFERENCES.
Traditional vaccine efficacy trials usually use fixed designs with fairly large sample sizes. Recruiting a large number of subjects requires longer time and higher costs. Furthermore, vaccine developers are more than ever facing the need to accelerat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41f8c8fbabe749c4901f47059fa5ad2f
https://pubmed.ncbi.nlm.nih.gov/36606496
https://pubmed.ncbi.nlm.nih.gov/36606496